ARIAD Pharmaceuticals (ARIA): $0.81 million was the positive money flow into the stock on Friday and the up/down ratio of ticks was also in favor of the bulls at 1.24. The value of trades done on upticks was $4.18 million, whereas, trades done on downticks were valued at $3.37 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $1.12 million worth stocks on upticks, which is a bullish indication. The downticks accounted only for $0.35 million worth of block trades showing a lack of interest among the large traders to sell the stock down. The up/down ratio of 3.21 was strongly in favor of the bulls. The money flow in block trades was $0.77 million. ARIAD Pharmaceuticals (ARIA) fell $0.05 traded at $10.14, a change of -0.49% over the previous day. The stock is -1.07% for the week.
The company Insiders own 8.2% of ARIAD Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -20.77% . Institutional Investors own 72% of ARIAD Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -21.01%.
In a related news, The Securities and Exchange Commission has divulged that Clackson Timothy P, officer (President, R&D, CSO) of Ariad Pharmaceuticals Inc, had unloaded 19,436 shares at an average price of $10.47 in a transaction dated on August 22, 2016. The total value of the transaction was worth $203,495.
ARIAD Pharmaceuticals (NASDAQ:ARIA): stock was range-bound between the intraday low of $9.88 and the intraday high of $10.21 after having opened at $10.21 on Fridays session. The stock finally closed in the red at $10.21, a loss of -0.69%. The stock remained in the red for the whole trading day. The total traded volume was 2,807,620 shares. The stock failed to cross $10.21 in Fridays trading. The stocks closing price on Thursday was $10.19.
ARIAD Pharmaceuticals (ARIA) : During the past 4 weeks, traders have been relatively bearish on ARIAD Pharmaceuticals (ARIA), hence the stock is down -0.26% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.76% relative to the S&P 500. The 4-week change in the price of the stock is -0.39% and the stock has fallen -1.27% in the past 1 week.
ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).